AcroMeta Group Limited (SGX: 43F) has announced a strategic partnership with Macro HRD SG Pte. Ltd., a Singapore-based management consultancy for the healthcare sector, to enter the ambient temperature cellular logistics (ATCLS) market. The non-binding term sheet outlines AcroMeta's acquisition of a strategic stake in Macro-ATCLS Pte. Ltd., the commercial vehicle for the technology, and an option to acquire an exclusive license to deploy the platform across Southeast Asia.
The ATCLS technology is designed to transform the transportation of living cells and temperature-sensitive biological materials by eliminating the need for conventional refrigerated and cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and process control. This allows dormant living cells to be transported at ambient temperature and reactivated at the point of use.
The markets addressed include stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, and organ transplantation. Macro's project materials cite market sizes ranging from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, with the global cell-and-gene-therapy third-party logistics market estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035, a 25.1% CAGR. ATCLS estimates a serviceable addressable market of approximately US$14.5 billion by 2032.
Commenting on the partnership, Mr Lawrence Toh, Executive Director of AcroMeta, said, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
The exclusive licensing arrangement for Southeast Asia would grant AcroMeta rights to develop and commercialise the ATCLS business in agreed territories, including the ability to appoint sub-licensees and a first right to acquire additional territories. This structure is intended to expand AcroMeta's commercial reach significantly across the region.
The Group intends to continue evaluating strategic opportunities to support long-term value creation for shareholders, with a focus on disciplined capital allocation. This move aligns with AcroMeta's strategy to diversify beyond its core facility management services, leveraging the high-growth potential of cell and gene therapy logistics.
For more information on AcroMeta, visit www.AcroMeta.com. The original release is available at www.newmediawire.com.
